FrancophonIA/ELRC3.0 huggingface dataset:
English: 10 vials (powder) + 10 pre-filled syringes with needle (solvent).
Estonian: 10 (pulbri)viaali +10 nõelaga (lahusti)süstlit.
English: Withdraw the entire content of the solvent vial into a syringe.
Estonian: Tõmba kogu lahustiviaali sisu süstlasse.
English: ProQuad is not indicated in this subset of the paediatric population.
Estonian: Selles laste alarühmas ei ole ProQuadi kasutamine näidustatud.
English: ProQuad powder and solvent for suspension for injection Measles, mumps, rubella and varicella vaccine (live)
Estonian: ProQuad Süstesuspensiooni pulber ja lahusti Leetrite, mumpsi, punetiste ja tuulerõugete vaktsiin (elus)
English: ProQuad powder and solvent for suspension for injection in a pre-filled syringe Measles, mumps, rubella and varicella vaccine (live)
Estonian: ProQuad Süstesuspensiooni pulber ja lahusti süstlis Leetrite, mumpsi, punetiste ja tuulerõugete vaktsiin (elus)
English: No clinical data are available for ProQuad administered after exposure to measles, mumps, rubella, or varicella.
Estonian: ProQuadi manustamise kohta leetrite, mumpsi, punetiste või tuulerõugetega kokkupuute järgselt puuduvad kliinilised andmed.
English: Tel.: +420 233 010 111 dpoc_czechslovak@merck.com
Estonian: Česká republika Merck Sharp & Dohme s. r. o. Tel: +420.233.010.111 dpoc_czechslovak@merck.com
English: International non-proprietary name (INN): miglustat
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): miglustaat
English: Information was available from 23 patients.
Estonian: Andmeid oli 23 patsiendi kohta.
English: This is expected to reduce the symptoms of the disease.
Estonian: See aitab eeldatavalt selle haiguse sümptomeid leevendada.
English: The disease can result in dementia and is usually fatal before the patient has reached adulthood.
Estonian: Haigus võib põhjustada dementsust ning lõpeb tavaliselt surmaga enne patsiendi täiskasvanuikka jõudmist.
English: The medicine was also studied in 12 patients aged less than 12 years.
Estonian: Ravimit uuriti ka 12 patsiendil vanuses alla 12 aasta.
English: The study compared the effects of adding Zavesca taken at a dose of 200 mg three times a day to standard care with the effects of standard care alone.
Estonian: Uuringus võrreldi Zavesca toimet selle lisamisel annuses 200 mg kolm korda päevas tavapärasele ravile ainult tavapärase ravi kasutamisega.
English: Symptoms include a progressive loss of co-ordination, problems with ‘saccadic' (rapid) eye movements that can lead to impaired vision, delayed development, difficulty swallowing, increased muscle tone, fits, and learning difficulties.
Estonian: Sümptomiteks on progresseeruv koordinatsioonivõime halvenemine, sakaadiliste (aktiivse vaatlemisega seotud kiirete) silmaliigutuste häired, mis võivad halvendada nägemist, arengupeetus, neelamisraskused, lihastoonuse tõus, krambid ja õppimisraskused.
English: The medicine showed a very limited benefit in the main study: there was only a marginal difference in the change in the speed of eye movements between the patients taking Zavesca and those receiving standard care, and there were uncertainties over whether looking at eye movements was the best way to measure the medicine's effectiveness.
Estonian: Ravimi kasulikkus põhiuuringus oli väga väike: Zavescat kasutanud patsientide ja tavapärast ravi kasutanud patsientide silmaliigutuste kiiruse vahe oli väga väike ning ei olnud kindel, kas silmaliigutuste jälgimine on parim viis ravimi efektiivsuse mõõtmiseks.
English: The effectiveness of Zavesca has been studied in one main study involving 29 patients aged 12 years and over with Niemann Pick type C disease.
Estonian: Zavesca efektiivsust uuriti ühes põhiuuringus, milles osales 29 vähemalt 12-aastast C-tüüpi NiemanniPicki tõvega patsienti.
English: What is happening for Zavesca for the treatment of type 1 Gaucher disease?
Estonian: Mis toimub Zavesca kasutamisel I tüüpi Gaucher' tõve raviks?
English: Ref. EMEA/121008/2008
Estonian: London, 19. märts 2008 Dokumendi nr EMEA/186544/2008
English: was the change in the speed at which the patients made saccadic horizontal eye movements after a year's treatment.
Estonian: Efektiivsust mõõdeti põhiliselt patsientidel sakaadiliste horisontaalsete silmaliigutuste kiiruses pärast üheaastast ravi toimunud muutuse järgi.
English: There are no consequences on the use of Zavesca in its authorised indication, for which the balance of benefits and risks remains unchanged.
Estonian: Tagasivõtmine ei avalda mõju Zavesca kasutamisele nende näidustuste raviks, mille kohta on müügiluba juba antud ning mille korral jääb kasulikkuse ja riski suhe muutumatuks.
English: By preventing the enzyme from working, miglustat can reduce the production of glycosphingolipids in cells.
Estonian: Ensüümi toime pärssimisega võib miglustaat vähendada glükosfingolipiidide teket rakkudes.
English: The company also presented additional information from a worldwide survey of patients with Niemann Pick type C disease who had been treated with miglustat outside of the main study.
Estonian: Ettevõte esitas lisateavet ka ülemaailmse C-tüüpi Niemanni-Picki tõvega patsientide uuringu tulemuste kohta, milles patsiente oli ravitud väljaspool põhiuuringut miglustaadiga.
English: On 19 February 2008, Actelion Registration Ltd. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new indication for Zavesca, in the treatment of neurological manifestations in patients with Niemann Pick type C disease.
Estonian: 19. veebruaril 2008 teatas Actelion Registration Ltd ametlikult inimravimikomiteele oma soovist võtta tagasi uue näidustusena C-tüüpi Niemanni-Picki tõve neuroloogiliste sümptomite raviks kasutada kavatsetud ravimi Zavesca müügiloa taotlus.
English: Zavesca is a hard white capsule, which contains the active substance miglustat.
Estonian: Zavesca on valge kõvakapsel, mis sisaldab toimeainena miglustaati.
English: It is used for the treatment of mild to moderate type 1 Gaucher disease.
Estonian: Seda kasutatakse kerge või mõõduka I tüüpi Gaucher' tõve raviks.
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials or compassionate use programmes with Zavesca.
Estonian: Ettevõte teatas inimravimikomiteele, et praegu Zavesca kliinilistes uuringutes või erilaoga kasutamise programmides osalevatele patsientidele tagasivõtmine mõju ei avalda.
English: What are the consequences of the refusal for patients in clinical trials or compassionate use programmes using Zavesca?
Estonian: Kuidas mõjutab tagasivõtmine praegu Zavesca kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente?
English: Zavesca was designated as an orphan medicinal product on 16 February 2006 for Niemann Pick type C disease.
Estonian: 16. veebruaril 2006 nimetati Zavesca harvikravimiks, millega ravitakse C-tüüpi Niemanni-Picki tõbe.
English: Based on the review of the data and the company's response to the CHMP's list of questions, at the time of the withdrawal, the CHMP had given a negative opinion and did not recommend the approval of Zavesca for the treatment of neurological manifestations in patients with Niemann Pick type C disease.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimikomitee esitatud küsimustele, oli komitee andnud taotluse tagasivõtmise ajal negatiivse arvamuse ega soovitanud anda Zavescale Ctüüpi Niemanni-Picki tõve neuroloogiliste sümptomite ravis kasutamiseks müügiluba.
English: Niemann Pick type C disease is a rare inherited disease that affects the way the body handles fats.
Estonian: C-tüüpi Niemanni-Picki tõbi on harvaesinev pärilik haigus, mis mõjutab rasvade ainevahetust organismis.
English: Gaucher disease is a rare, inherited disease that affects the way the body handles fats.
Estonian: Gaucher' tõbi on harvaesinev pärilik haigus, mis mõjutab rasvade ainevahetust organismis.
English: The CHMP acknowledged that there are no alternative treatments for Niemann Pick type C disease, but it was concerned that a benefit of Zavesca in the treatment of the neurological symptoms of Niemann Pick type C disease had not been sufficiently demonstrated.
Estonian: Inimravimikomitee möönis, et C-tüüpi Niemanni-Picki tõve muu ravi puudub, kuid nägi põhjust ettevaatlikkuseks seetõttu, et Zavesca kasulikkust C-tüüpi Niemanni-Picki tõve neuroloogiliste sümptomite ravis ei olnud piisavalt tõestatud.
English: The effects of Zavesca were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Zavesca toimet muude katsetega.
English: In patients with this disease, fatty substances such as ‘glycosphingolipids' build up within cells in the brain, as well as elsewhere in the body.
Estonian: Selle haigusega patsientidel ladestub ajurakkudesse ja mujale organismis rasvaineid glükosfingolipiide.
English: QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE APPLICATION FOR A CHANGE TO THE MARKETING AUTHORISATION for ZAVESCA
Estonian: TEAVE MÜÜGILOA MUUTMISTAOTLUSE TAGASIVÕTMISE KOHTA ZAVESCA
English: What was Zavesca expected to be used for?
Estonian: Milleks kavatseti Zavescat kasutada?
English: Therefore, at that point in time, the CHMP was of the opinion that the benefits of Zavesca in the treatment of neurological manifestations in Niemann Pick type C disease did not outweigh its risks.
Estonian: Inimravimikomitee oli tagasivõtmise ajal seepärast arvamusel, et Zavesca kasulikkus C-tüüpi Niemanni-Picki tõve neuroloogiliste sümptomite ravis ei ületa ravimiga kaasnevaid riske.
English: Zavesca was also linked to side effects affecting the stomach and gut, as well as cases of weight loss and thrombocytopenia (low blood platelet counts).
Estonian: Zavesca kasutamisega kaasnes ka mao ja soolte kõrvalnähte, samuti kehakaalu languse ja trombotsütopeenia (trombotsüütide vähesus) juhte.
English: In the new indication, Zavesca was expected to be used to treat the ‘neurological' symptoms of Niemann Pick type C disease (affecting the brain and nervous system).
Estonian: Uue näidustuse puhul kavatseti Zavescat kasutada C-tüüpi (aju ja närvisüsteemi kahjustava) Niemanni-Picki tõve neuroloogiliste sümptomite raviks.
English: In patients with this disease, a fatty substance called glucosylceramide builds up in different parts of the body, such as the spleen, liver, and bones.
Estonian: Selle haigusega patsientidel koguneb eri kehaosadesse, näiteks põrna, maksa ja luudesse, rasvainet glükosüültseramiidi.
English: How is Zavesca expected to work?
Estonian: Milline on Zavesca eeldatav toime?
English: Miglustat, the active substance in Zavesca, prevents an enzyme called ‘glucosylceramide synthase' from working.
Estonian: Zavescas toimeainena sisalduv miglustaat pärsib ensüümi glükosüültseramiidsüntaasi toimet.
English: Treatment lasts from 5 to 14 days.
Estonian: Ravi kestab 5-14 päeva.
English: Each infusion should last between 30 and 60 minutes.
Estonian: Iga infusioon peab kestma 30-60 minutit.
English: What measures are being taken to ensure the safe and effective use of Tygacil?
Estonian: Mis meetmed võetakse, et tagada Tygacili ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Tygacil on 24 April 2006.
Estonian: Euroopa Komisjon andis Tygacili müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 24. aprillil
English: The full EPAR for Tygacil can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Tygacili kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Tygacil tigecycline
Estonian: Tygacil tigetsükliin
English: A risk management plan has been developed to ensure that Tygacil is used as safely and effectively as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Tygacili võimalikult ohutu kasutamine.
English: Before using Tygacil, doctors should consider official guidance on the appropriate use of antibiotics.
Estonian: Enne Tygacili kasutamist peab arst arvesse võtma antibiootikumide asjakohase kasutamise ametlikke juhiseid.
English: In all of the studies, the main measure of effectiveness was the number of patients whose infection was cured.
Estonian: Kõigis uuringutes oli efektiivsuse põhinäitaja patsientide arv, kelle infektsioon paranes.
English: The length of treatment depends on where the infection is, how severe it is, and the patient's response to treatment.
Estonian: Ravi pikkus sõltub infektsiooni kohast, raskusest ja patsiendi ravivastusest.
English: By blocking the production of new proteins, the bacteria cannot multiply and they eventually die.
Estonian: Kui uusi valke ei teki, ei saa bakterid paljuneda ja lõpuks hävivad.
English: Patients allergic to tetracycline antibiotics may also be allergic to Tygacil.
Estonian: Tetratsükliinantibiootikumide suhtes allergilised patsiendid võivad olla allergilised ka Tygacili suhtes.
English: The CHMP decided that Tygacil's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Tygacili kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: In children above eight years of age, treatment is only given after consulting with a doctor with appropriate experience in the management of infectious diseases, and should be given as an infusion over a period of 60 minutes.
Estonian: Vähemalt 8-aastastele lastele tohib ravimit anda üksnes pärast infektsioonide ravis kogenud arstiga konsulteerimist ning seda tuleb manustada 60 minutit kestva infusioonina.
English: Doses are lower in patients with severe liver problems.
Estonian: Annused on väiksemad raskete maksaprobleemidega patsientidel.
English: Why has Tygacil been approved?
Estonian: Miks Tygacil heaks kiideti?
English: Tygacil should be used only when other antibiotics are not suitable.
Estonian: Tygacili tohib kasutada ainult siis, kui ravi muude antibiootikumidega ei sobi.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tygacil, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Tygacili omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Although there are few data in children, studies suggest that Tygacil can be a treatment alternative for complicated skin and soft tissue or abdominal infections, with bacteria resistant to other antibiotics.
Estonian: Kuigi laste kohta on vähe andmeid, viitavad uuringud, et tüsistunud naha- ja nahaaluskudede infektsioonide ja kõhukoopa infektsioonide korral võib Tygacil olla alternatiivne ravivõimalus, kui bakterid on resistentsed muudele antibiootikumidele.
English: For more information about treatment with Tygacil, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Tygaciliga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Other information about Tygacil:
Estonian: Muu teave Tygacili kohta
English: Tygacil has been compared with other antibiotics in four main studies.
Estonian: Tygacili võrreldi teiste antibiootikumidega neljas põhiuuringus.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tygacil.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Tygacil must not be used in people who are hypersensitive (allergic) to tigecycline or any of the other ingredients.
Estonian: Tygacili ei tohi kasutada patsiendid, kes on tigetsükliini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: What is the risk associated with Tygacil?
Estonian: Mis riskid Tygaciliga kaasnevad?
English: In the four main studies, Tygacil was as effective as the comparator antibiotics.
Estonian: Neljas põhiuuringus oli Tygacil sama efektiivne kui võrdlusantibiootikumid.
English: This document is a summary of the European Public Assessment Report (EPAR) for Tygacil.
Estonian: See on ravimi Tygacil Euroopa avaliku hindamisaruande kokkuvõte.
English: In adults, the recommended dose of Tygacil is a starting dose of 100 mg, followed by 50 mg every 12 hours for five to 14 days.
Estonian: Täiskasvanutel on Tygacili soovituslik algannus 100 mg, mille järgneb 50 mg iga 12 tunni järel 5-14 päeva jooksul.
English: For the full list of all side effects reported with Tygacil, see the package leaflet.
Estonian: Tygacili kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: It is also used to treat complicated infections in the abdomen.
Estonian: Ravimit kasutatakse ka kõhukoopa tüsistunud infektsioonide raviks.
English: In the other two studies, Tygacil was compared with imipenem/cilastatin (a combination of two medicines used together as an antibiotic) in 1,568 patients with complicated infections in the abdomen.
Estonian: Kahes teises uuringus võrreldi Tygacili imipeneemi ja tsilastatiini kombinatsiooniga (antibiootikumina kasutatav kahe ravimi kombinatsioon) 1568 patsiendil, kellel oli tüsistunud kõhukoopa infektsioon.
English: The most common side effects with Tygacil are mild to moderate nausea (feeling sick) and vomiting, seen in 20% and 14% of patients, respectively.
Estonian: Tygacili kõige sagedamad kõrvalnähud on kerge või mõõdukas iiveldus ja oksendamine, mis esines vastavalt 20%-l ja 14%-l patsientidest.
English: What benefit has Tygacil shown during the studies?
Estonian: Milles seisnes uuringute põhjal Tygacili kasulikkus?
English: In children from 12 to 18 years a dose of 50 mg is given every 12 hours for a period of 5 to 14 days.
Estonian: 12-18aastastele noortele manustatakse 50 mg annus iga 12 tunni järel 5-14 päeva jooksul.
English: In the study looking at diabetic foot infections, Tygacil was less effective than ertapenem: 78% of the patients receiving Tygacil were cured, compared with 83% of those receiving ertapenem.
Estonian: Jalainfektsioonidega diabeedihaigete uuringus oli ertapeneem Tygacilist efektiivsem: 78% Tygacili saanud patsientidest paranes, ertapeneemi saanutest paranes 83%.
English: How does Tygacil work?
Estonian: Kuidas Tygacil toimib?
English: An additional study compared Tygacil with the antibiotic ertapenem in 813 diabetic patients with moderate to severe foot infections.
Estonian: Lisauuringus võrreldi Tygacili ja antibiootikumi ertapeneemi toimet 813 diabeediga patsiendil, kellel olid mõõdukad kuni rasked jalainfektsioonid.
English: In the studies of abdominal infection, around 86% of the patients receiving either Tygacil or imipenem/cilastatin were cured.
Estonian: Kõhukoopa infektsioonide uuringutes paranes ligikaudu 86% patsientidest, kes said kas Tygacili või imipeneemi ja tsilastatiini kombinatsiooni.
English: The active substance in Tygacil, tigecycline, belongs to a group of antibiotics called ‘glycylcyclines'.
Estonian: Tygacili toimeaine tigetsükliin kuulub antibiootikumide glütsüültsükliinide rühma.
English: Tygacil is used to treat adults and children older than eight years with complicated infections of the skin and soft tissue (the tissue below the skin), but not foot infections in people with diabetes.
Estonian: Tygacili kasutatakse täiskasvanute ja vähemalt 8-aastaste laste naha ja pehmete nahaaluskudede tüsistunud infektsioonide (v.a diabeetiliste jalainfektsioonide) raviks.
English: It works by blocking the bacteria's ribosomes, the parts of the cell where new proteins are made.
Estonian: Tigetsükliin blokeerib bakterite ribosoome - raku osi, kus tekivad uued valgud.
English: In two of these studies, Tygacil was compared with the combination of vancomycin and aztreonam in 1,129 patients with complicated skin and soft tissue infections (not including infected diabetic foot ulcers).
Estonian: Neist kahes uuringus võrreldi Tygacili vankomütsiini ja astreonaami kombinatsiooniga 1129 patsiendil, kellel olid tüsistunud naha- ja nahaaluskudede infektsioonid (v.a diabeetilised infektsioossed jalahaavandid).
English: The list of bacteria against which Tygacil is active can be found in the summary of product characteristics (also part of the EPAR).
Estonian: Tygacili suhtes tundlike bakterite loetelu on ravimi omaduste kokkuvõttes (samuti Euroopa avaliku hindamisaruande osa).
English: In children from 8 to 12 years old a dose of 1.2 mg per kilogram body weight is given by infusion into a vein every twelve hours, up to a maximum dose of 50 mg every 12 hours.
Estonian: 8-12-aastastele lastele manustatakse ravimit iga 12 tunni järel veeni tilgutatava lahusena annuses 1,2 mg kehamassi kilogrammi kohta.
English: In the studies of skin and soft tissue infections, around 86% of the patients receiving Tygacil were cured, compared with around 89% of those receiving vancomycin and aztreonam.
Estonian: Naha- ja nahaaluskudede infektsioonide uuringutes paranes ligikaudu 86% Tygacili saanud patsientidest, vankomütsiini ja astreonaami saanutest paranes ligikaudu 89%.
English: What is Tygacil used for?
Estonian: Milleks Tygacili kasutatakse?
English: How is Tygacil used?
Estonian: Kuidas Tygacili kasutatakse?
English: How has Tygacil been studied?
Estonian: Kuidas Tygacili uuriti?
English: The medicine can only be obtained with a prescription.
Estonian: Tygacil on retseptiravim.
English: The European Commission granted a marketing authorisation valid throughout the EU for Zalasta to KRKA, d.d., Novo mesto on 27 September 2007.
Estonian: Euroopa Komisjon väljastas Zalasta müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele KRKA, d.d., Novo mesto 27. septembril 2007.
English: Patients over 65 years of age and patients who have problems with their liver or kidneys may need a lower starting dose of 5 mg per day.
Estonian: Üle 65-aastased patsiendid ning neeru- või maksaprobleemidega patsiendid võivad vajada väiksemat algannust 5 mg päevas.
English: It is known as an ‘atypical' antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s.
Estonian: Seda nimetatakse ebatüüpiliseks antipsühhootikumiks, kuna see erineb vanematest antipsühhootilistest ravimitest, mida on turustatud alates 1950-ndatest aastatest.
English: The Committee recommended that Zalasta be given marketing authorisation.
Estonian: Komitee soovitas anda Zalastale müügiloa.
English: It is available as round, yellow tablets (2.5, 5, 7.5, 10, 15 and 20 mg) and as round, yellow ‘orodispersible' tablets (5, 7.5, 10, 15 and 20 mg).
Estonian: Seda turustatakse ümmarguste kollaste tablettidena (2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg ja 20 mg) ja ümmarguste kollaste suus dispergeeruvate tablettidena (5 mg, 7,5 mg, 10 mg, 15 mg ja 20 mg).
English: Schizophrenia is a mental illness that has a number of symptoms including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs).
Estonian: Skisofreenia on psüühikahaigus, millel on mitmesugused sümptomid, sealhulgas mõtlemis- ja kõnehäired, hallutsinatsioonid (ebareaalsete asjade nägemine või kuulmine), kahtlustamine ja pettekujutlused.
English: Since these neurotransmitters are involved in schizophrenia and bipolar disorder, olanzapine helps to normalise the activity of the brain, reducing the symptoms of these diseases.
Estonian: Kuna need neurotransmitterid osalevad skisofreenia ja bipolaarse meeleoluhäire tekkimisel, aitab olansapiin ajutegevust normaliseerida, vähendades kõnealuste haiguste sümptomeid.